Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Abivax Closes $800 Million ADS Offering and Nears $11 Billion Valuation

Proceeds will fund planned U.S. commercialization plus late‑stage trials and carry operations through the second quarter of 2029.

Stories older than 24h

Pfizer Lung Cancer Drug Fails to Improve Survival in Late‑Stage Trial

Pakistan Genome Resource Maps Thousands of Human Gene Knockouts

Experimental Antibody Preserves Muscle During Tirzepatide Weight Loss

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

Daraxonrasib Nearly Doubles Median Survival in Previously Treated Metastatic Pancreatic Cancer

Praxis Drug Vormatrigine Misses Primary Goal in Phase 2/3 POWER1 Trial

Daraxonrasib Doubles Survival in Treated Metastatic Pancreatic Cancer in Phase 3 Trial

Ivonescimab Extends Survival in China Phase 3 Trial for Squamous Lung Cancer

Mezigdomide Triplet Cuts Risk of Myeloma Progression by 52% in Phase 3 Trial

FDA Extends Review of AstraZeneca’s Camizestrant

Brazil Approves 24‑Hour Subcutaneous Levodopa Therapy for Advanced Parkinson

Biogen and Denali Halt BIIB122 Program After Phase 2b Parkinson’s Trial Fails

EMA Recommends Jascayd for Two Progressive Lung Fibrosis Conditions

EMA Recommends Etcamah for ESR1‑Mutant Advanced Breast Cancer

BioMarin Says Voxzogo Raised Growth Rates in Children With Hypochondroplasia

Bristol Myers Squibb to Deploy Anthropic’s Claude Across Global Operations

Kissei Discloses 20 Deaths in Japan Among Tabneous Users

Kissei Tells Japan Doctors to Halt New Tavneos Use After 20 Deaths Reported

FDA Places Full Clinical Hold on Aardvark’s ARD-101 Prader–Willi Trials